📊 KMTS Key Takeaways
Is Kestra Medical Technologies, Ltd.. (KMTS) a Good Investment?
Kestra Medical is a pre-profitable medical device company with exceptional revenue growth (115% YoY) and a fortress balance sheet ($291M cash, 7.32x current ratio), but faces severe operational challenges with -$88.2M negative free cash flow and an operating margin of -143.5%, indicating unsustainable unit economics without significant operational leverage improvements.
Kestra is scaling rapidly with 115% YoY revenue growth and ~50% gross margins, indicating solid early unit economics. Yet operating losses remain deep (operating margin -143%, FCF margin -133%), and a clear path to operating leverage is not evident. A robust cash position and low leverage provide ample runway to execute on efficiency and commercialization.
Why Buy Kestra Medical Technologies, Ltd.. Stock? KMTS Key Strengths
- Exceptional top-line growth of 115% YoY demonstrating strong market demand
- Fortress balance sheet with $291.3M in cash and minimal debt (0.15x D/E ratio) providing 3+ years of runway
- Healthy gross margin of 49.9% indicating viable core product economics
- Net losses improving 9.8% YoY suggesting operational trajectory toward profitability
- Excellent liquidity with 7.32x current ratio providing financial flexibility
- Triple-digit revenue growth (+115% YoY)
- Healthy ~50% gross margin supporting unit economics
- Strong liquidity and low leverage (cash-rich, 7.3x current ratio, 0.15x D/E)
KMTS Stock Risks: Kestra Medical Technologies, Ltd.. Investment Risks
- Severe unprofitability with -$139.5% net margin and -$143.5% operating margin indicating massive SG&A/R&D spend relative to revenue
- Negative operating cash flow of -$63.0M and negative free cash flow of -$88.2M showing company burns $1.33 for every $1.00 in revenue
- No visible path to profitability in current trajectory requiring dramatic margin expansion or revenue acceleration to achieve breakeven
- Medical device sector execution risk with long development and commercialization cycles vulnerable to regulatory, clinical, or market adoption delays
- Cash burn rate of $88.2M annually will require either additional capital raises or rapid profitability improvements within 3+ years
- Sustained heavy operating losses and negative free cash flow
- Uncertain timeline to profitability; interest coverage not meaningful
- Potential future dilution/financing if burn persists beyond runway
Key Metrics to Watch
- Operating cash flow trajectory and path to positive OCF relative to revenue growth
- Gross margin sustainability and expansion potential as manufacturing scales
- Operating expense ratio relative to revenue - need to see SG&A and R&D leverage
- Quarterly revenue growth sustainability - whether 115% growth rate can be maintained
- Free cash flow breakeven timeline and cash runway depletion estimates
- Operating margin and opex as a % of revenue
- Free cash flow margin and cash burn vs. cash balance
Kestra Medical Technologies, Ltd.. (KMTS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 7.32x current ratio provides a solid financial cushion.
KMTS Profit Margin, ROE & Profitability Analysis
KMTS vs Healthcare Sector: How Kestra Medical Technologies, Ltd.. Compares
How Kestra Medical Technologies, Ltd.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Kestra Medical Technologies, Ltd.. Stock Overvalued? KMTS Valuation Analysis 2026
Based on fundamental analysis, Kestra Medical Technologies, Ltd.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Kestra Medical Technologies, Ltd.. Balance Sheet: KMTS Debt, Cash & Liquidity
KMTS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Kestra Medical Technologies, Ltd..'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-5.07 indicates the company is currently unprofitable.
KMTS Revenue Growth, EPS Growth & YoY Performance
KMTS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $15.1M | -$21.5M | $-0.61 |
| Q2 2025 | $14.7M | -$20.4M | $-0.64 |
| Q1 2025 | $12.8M | -$19.9M | $-0.50 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Kestra Medical Technologies, Ltd.. Dividends, Buybacks & Capital Allocation
KMTS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Kestra Medical Technologies, Ltd.. (CIK: 0001877184)
📋 Recent SEC Filings
❓ Frequently Asked Questions about KMTS
What is the AI rating for KMTS?
Kestra Medical Technologies, Ltd.. (KMTS) has a Combined AI Rating of HOLD from Claude (HOLD) and ChatGPT (HOLD) with 64% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are KMTS's key strengths?
Claude: Exceptional top-line growth of 115% YoY demonstrating strong market demand. Fortress balance sheet with $291.3M in cash and minimal debt (0.15x D/E ratio) providing 3+ years of runway. ChatGPT: Triple-digit revenue growth (+115% YoY). Healthy ~50% gross margin supporting unit economics.
What are the risks of investing in KMTS?
Claude: Severe unprofitability with -$139.5% net margin and -$143.5% operating margin indicating massive SG&A/R&D spend relative to revenue. Negative operating cash flow of -$63.0M and negative free cash flow of -$88.2M showing company burns $1.33 for every $1.00 in revenue. ChatGPT: Sustained heavy operating losses and negative free cash flow. Uncertain timeline to profitability; interest coverage not meaningful.
What is KMTS's revenue and growth?
Kestra Medical Technologies, Ltd.. reported revenue of $66.5M.
Does KMTS pay dividends?
Kestra Medical Technologies, Ltd.. does not currently pay dividends.
Where can I find KMTS SEC filings?
Official SEC filings for Kestra Medical Technologies, Ltd.. (CIK: 0001877184) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is KMTS's EPS?
Kestra Medical Technologies, Ltd.. has a diluted EPS of $-1.76.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is KMTS a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Kestra Medical Technologies, Ltd.. has a HOLD rating with 64% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is KMTS stock overvalued or undervalued?
Valuation metrics for KMTS: ROE of -32.2% (sector avg: 15%), net margin of -139.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy KMTS stock in 2026?
Our dual AI analysis gives Kestra Medical Technologies, Ltd.. a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is KMTS's free cash flow?
Kestra Medical Technologies, Ltd..'s operating cash flow is $-63.0M, with capital expenditures of $25.2M. FCF margin is -132.7%.
How does KMTS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -139.5% (avg: 12%), ROE -32.2% (avg: 15%), current ratio 7.32 (avg: 2).